Cytokinetics vs Xilio Therapeutics
Cytokinetics is the larger business, with $88.0m of revenue in fiscal 2025 against $43.8m for Xilio Therapeutics (2.0 times as much). Xilio Therapeutics grew faster (589.9% against 376.6%). Xilio Therapeutics kept more of each dollar of sales as profit: a net margin of -80.1% against -891.6%.
| Latest fiscal year | CytokineticsCYTK, 2025 | Xilio TherapeuticsXLO, 2025 |
|---|---|---|
| Revenue | $88.0m | $43.8m |
| Revenue growth | 376.6% | 589.9% |
| Net income | −$785m | −$35.0m |
| Operating margin | -695.4% | -95.9% |
| Net margin | -891.6% | -80.1% |
| Return on equity | — | -132.5% |
| Free cash flow | −$535m | −$5.5m |
| Cash | $123m | $138m |
| Total debt | $999m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 673 | 76 |
| Market value | $7.69bn | $56.6m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | — |
| Insider trades, 12 months | 0 buys, 85 sales | 1 buys, 2 sales |